Lupin partners with Boehringer lngelheim

04 Sep 2019 Evaluate

Lupin and Boehringer lngelheim have entered into licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin's lead MEK inhibitor compound in combination with one of Boehringer lngelheim's innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

683.25 -8.15 (-1.18%)
May 18, 16:03 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 899.00
Cipla 953.00
Dr. Reddy's Lab 3913.25
Aurobindo Pharma 559.45
Lupin 683.25
View more..